Business NewsRadical ConsumeristSilicon Valley InsiderWealthy Biotech Trader

Capitalist Countdown: Wealthy VC’s Top 5 Investing News Stories of the Week

Welcome to the Capitalist Countdown By Wealthy VC

The Capitalist Countdown is a weekly series that features the biggest stories from the market’s hottest stocks as well as news from under-the-radar hidden gems, capable of delivering mutibagger returns to your portfolio.

With that said, please sit back, relax and enjoy the Capitalist Countdown’s top 5 market-moving news stories for the week of November 22nd – 28th, 2021.

5. Elon Musk Follows Through on Twitter Poll, Sells Nearly $7 Billion in Tesla Stock

Love Him or Hate Him, Elon Musk Seems to Follow Through When He Says He’s Going to Do Something, No Matter How Outlandish it May Seem

Even if that means unloading 10% of his Tesla (NASDAQ: TSLA) (FRA: TL0) holding based on the results of a Twitter (NYSE: TWTR) poll. When the richest man on Earth posted a Twitter poll asking his followers if he should sell 10% of his Tesla shares so he would realize his capital gains and thus be taxed, many people thought it was just another joke. Musk assured the world that he would follow through on his stock liquidation if the public voted for it.

READ FULL MUSK TSLA ARTICLE

4. Pfizer’s Says its New COVID Pill Cuts Risks of Hospitalization, Death By 90%

Nearly Two Years Into the COVID-19 Pandemic and After Rigorous Testing, We’re Starting to See Some Game-Changing Medications Being Introduced to Combat the Virus’s Effects

Different from vaccines, which are administered with a shot and provide immunity via antibody development, many of the new COVID therapeutics are now coming in pill form and are designed to treat the virus rather than prevent it. Perhaps the most successful non-vaccine COVID-19 drug has been Pfizer’s (NYSE: PFE) orally administered pill PF-07321332 (working name). Pills are known to be more widely accepted than the injections that vaccines require, so Pfizer has high hopes for its acceptance by the general population. It is expected that Pfizer will market its new COVID pill under the brand name Paxlovid.

READ FULL PFIZER ARTICLE

Source: Shutterstock

3. 4 Social Media Stocks Worth Your Attention Not Named Facebook

As a Subsector of the Tech Sector, the Social Media Industry Offers an Enticing Option for Investors

We took a closer look at and examined these four top Big Tech stocks in the social media industry not named Facebook (NASDAQ: FB).

READ FULL SOCIAL MEDIA STOCKS ARTICLE

2. Plant-Based Food Leader Eat Well Group to Expand Investor Base With Listing on National U.S. Stock Exchange

The Plant-Based Food Industry Has Been One of the Hottest Sectors of the Last Few Years

Whether you’re at the grocery store or your favorite restaurant, you’ve likely seen plant-based food products for sale. While big-name plant-based brands like Beyond Meat (NASDAQ: BYND) and Tattooed Chef (NASDAQ: TTCF) are well-known and get plenty of attention, there are other, smaller companies that present investors with even more growth opportunities. Eat Well Group (CSE: EWG) (OTC: EWGFF) (FRA: 6BC0) is one such company. Eat Well is building a vertically integrated plant-based powerhouse with a leading plant-based CPG brand. Since the industry is still relatively new and growing exponentially, it’s ripe for consolidation, as well as huge investor gains.

READ FULL EAT WELL ARTICLE

1. After a Breakout Year in 2021, Here’s Why Regeneron Stock Has Even More Upside

For the Millions of Americans That Have Been Infected With COVID-19, Few Therapeutics Have Been More Effective at Treating the Virus Than Regeneron’s Monoclonal Antibodies Cocktail

Regeneron Pharmaceuticals’ (NYSE: REGN) (FRA: RGO) monoclonal antibodies cocktail REGEN-COV (casirivimab and imdevimab), which received emergency use authorization from the FDA in late 2020, has proven to be an extremely effective therapeutic for treating COVID-19. In fact, a recent study found that REGEN-COV could also be effective at preventing the virus as well, with the study showing that a single dose reduced the risk of contracting COVID-19 by 81.6%. Data from the late-stage trial also indicated that the antibodies cocktail has the potential to provide long-lasting immunity from COVID infection of up to eight months.

READ FULL REGENERON ARTICLE

???? Facebook Announces Name Change to ‘Meta’ in Cringeworthy Video, CEO Zuckerberg Dumps $25 Million in FB Stock

Did you enjoy this article? If so, consider signing up for the Wealthy VC Email Newsletter below to start receiving our weekly newsletter featuring the week’s best articles.

Follow Wealthy VC on Social Media: Facebook | Instagram | Twitter | LinkedIn | GETTR

????Join the Discussion in the Wealthy VC Investor Group

????Have a Stock Tip or News Story Suggestion? Email us at Invest@WealthyVC.com

Ryan Troup

Ryan Troup is the Editor in Chief of Wealthy VC and TCI. Ryan has 15+ years of investing experience. Twitter | Email

Related Articles

Back to top button